

Contents lists available at ScienceDirect

## **Diabetes Research and Clinical Practice**



journal homepage: www.journals.elsevier.com/diabetes-research-and-clinical-practice

# Diabetes stigma and weight stigma among physicians treating type 2 diabetes: Overlapping patterns of bias

### Brooke L. Bennett<sup>a</sup>, Rebecca M. Puhl<sup>a,b,\*</sup>

<sup>a</sup> Rudd Center for Food Policy & Health, University of Connecticut, 1 Constitution Plaza, Suite 600, Hartford, CT 06103, USA
<sup>b</sup> Department of Human Development and Family Sciences, University of Connecticut, 348 Mansfield Road, U-1058, Storrs, CT 06269-1058, USA

needed.

ARTICLE INFO	A B S T R A C T					
<i>Keywords:</i> Type 2 diabetes Diabetes stigma Weight stigma Internal medicine Endocrinology	Aims: Adults with type 2 diabetes (T2D) report experiencing stigma across multiple settings, including stigma- tizing interactions with their healthcare providers. However, research examining physician biases toward pa- tients with T2D is scarce. Identifying stigma-related barriers in diabetes care is essential to prevent providers' biases from impairing health care delivery. This study assessed attitudes towards individuals with T2D and obesity among physicians who treat T2D. <i>Methods:</i> Physicians specializing in internal medicine or endocrinology (n = 205) completed a series of online questionnaires assessing their attitudes towards patients with T2D and obesity, and their attributions of controllability and blame of individuals with T2D and obesity. <i>Results:</i> While 85% of physicians felt professionally prepared and confident to treat patients with T2D, 1/3 reported being repulsed by patients with T2D and view them as lazy (39%), lacking motivation (44%), and non-compliant with treatment (44%). Many witnessed professionals in their field making negative comments about patients with T2D (44%). Physicians endorsed worse levels of bias towards patients with obesity than T2D, but differences were small. <i>Conclusions:</i> Findings highlight the need for stigma reduction interventions for physicians addressing both T2D and obesity. Research assessing the effects of T2D stigma on quality of natient care and health outcomes is					

# 1. Introduction

The importance of improving quality of life for people with type 2 diabetes (T2D) [1] has increased attention to diabetes stigma in this population, leading to national and international calls for increased efforts to address stigma in clinical management of diabetes and as a research priority. The International Diabetes Federation has identified stigma as a priority and urgent problem to address [2], and the American Diabetes Association has prioritized the need to eliminate diabetes stigma and discrimination in their Health Equity Bill of Rights [3]. These declarations reflect the recognition that diabetes stigma is present and potentially harmful to people with diabetes, and reiterate the need for research to address this problem. To date, emerging research in this field has primarily investigated the nature and health correlates of diabetes stigma experienced among patients with T2D. Empirical evidence from Australia [4–7], Japan [8–11], and the U.S. [12–15] collectively document the prevalence and harmful health consequences of diabetes stigma for adults with T2D. For example, recent U.S. research suggests

that more than half of individuals with T2D perceive social stigma for having diabetes [13], and experience multiple forms of diabetes stigma including blame and judgement, differential treatment, and self-stigma [12]. Adults with T2D who report these stigmatizing experiences are more likely to engage in unhealthy eating behaviors, like binge eating and eating to cope with stress [15]. Additionally, adults who internalize diabetes stigma have higher diabetes-related distress, worse diabetes self-management, poorer quality interactions with doctors, and more unhealthy eating behaviors compared to those who do not internalize stigma [14,15]. Taken together, these findings point to the potential harms of diabetes stigma and the need to address this problem in clinical care.

Adding complexity to diabetes stigma is obesity, which commonly co-occurs with T2D [16]. Obesity itself is a highly stigmatized condition; prevalence rates of weight discrimination are as high as 41% among adults with obesity [17]. Thus, in addition to facing stigma due to their diabetes, people with T2D are also at risk of facing weight stigma at high body weights. There has been little acknowledgement of the

https://doi.org/10.1016/j.diabres.2023.110827

Received 24 February 2023; Received in revised form 29 June 2023; Accepted 12 July 2023 Available online 13 July 2023 0168-8227/© 2023 Elsevier B.V. All rights reserved.

<sup>\*</sup> Corresponding author at: Rudd Center for Food Policy and Health, University of Connecticut, 1 Constitution Plaza, Suite 600, Hartford, CT 06103, USA. *E-mail addresses:* brooke.bennett@uconn.edu (B.L. Bennett), rebecca.puhl@uconn.edu (R.M. Puhl).

vulnerability to weight stigma among people with T2D [18–20], despite extensive evidence that weight stigma is present in the healthcare setting and that physicians are one of the most common perpetrators of weight stigma reported by adults with obesity [21–23]. Recent evidence suggests that physician bias may extend to T2D, with 44% of adults with T2D reporting they feel stigmatized about their weight by doctors [12]. Further, experiencing weight stigma contributes to cardiometabolic risk factors that promote development of T2D, including elevated oxidative stress [24], C-reactive protein [25], increased risk of metabolic syndrome [26], weight gain [27], and elevated blood pressure [28] and blood glucose (HbA1c) [29]. Thus, weight stigma may not only undermine healthcare but also worsen health for people with T2D.

Collectively, this evidence indicates that adults with T2D perceive diabetes stigma in their healthcare experiences and are vulnerable to stigma stemming from both their diabetes and body weight. However, to date, scant research has studied stigmatizing attitudes, beliefs, or stereotypes expressed by healthcare providers about patients with T2D. An accurate understanding of diabetes stigma in healthcare cannot be achieved without first identifying the nature and extent of diabetes stigma expressed by healthcare providers, including their attributions and beliefs about diabetes and obesity that underlie their attitudes and behaviors toward patients with T2D. While evidence has documented weight stigma expressed by medical professionals toward patients with obesity [21,23], this work has not been extended to the diabetes field to assess diabetes stigma endorsed by healthcare providers treating patients with T2D. Identifying stigma-related barriers in diabetes care is essential to improve clinical practices that support patients with T2D in their diabetes self-management and lifestyle behaviors, and to prevent providers' biases from impairing health care delivery. Attitudes and biases of healthcare providers must be studied to inform the development of effective stigma-reduction interventions in healthcare.

To begin to address this research gap, the present study assessed diabetes stigma and weight stigma among physicians who treat patients with T2D. We aimed to identify the nature and extent of their stigmatizing attitudes and biases about patients with T2D, including physician characteristics associated with higher levels of stigmatizing attitudes. We predicted that physicians would express a moderate level of stigmatizing attitudes about patients with T2D, and that stigmatizing attitudes would be stronger towards patients with obesity than patients with T2D.

#### 2. Materials and methods

#### 2.1. Participants and procedures

The target sample for this study was physicians specializing in internal medicine or endocrinology who treat T2D. Participants were recruited by Interviewing Service of America (ISA), a national healthcare-oriented market research firm, with over 25,000 physicians enrolled in their U.S. panel. ISA panelists are required to provide validated geographic and demographic information to maintain membership. ISA validates their physician panelists through license numbers and National Provider Identifier (NPI) numbers. The panel management team verifies information entered by panelists including their qualifications and specialties by checking all publicly available information. Post validation, ISA sends internal surveys to the panelists who are highlighted for data quality issues are red flagged and those with persistent data quality issues are barred from taking any future surveys.

For the present study, ISA sent approximately 2100 email invitations to a random subsample of physicians (specializing in internal medicine or endocrinology) in their national physician panel. Participants who consented to participate were provided with the study survey link to complete a Qualtrics-hosted online screening questionnaire which assessed their training background, medical specialty, and clinical care of patients with diabetes. Participants who met eligibility criteria (a currently practicing physician in internal medicine or endocrinologist in the U.S. and treating patients with T2D) continued to the remaining set of questionnaires which assessed their attitudes towards patients with obesity and T2D, perceptions about providing treatment to these patients, beliefs about the causes of obesity and T2D, and sociodemographic backgrounds. Participants received a \$30 gift card for survey completion from ISA. Data collection occurred in January 2023. This study received approval from the University of Connecticut Institutional Review Board.

#### 2.2. Measures

Demographic Information and Professional Experience. Participants were asked to report their age, gender, race/ethnicity, height, and weight. Participants also indicated their training background, specialty area of medicine, work setting (e.g., inpatient, outpatient, etc.), years in practice, and the number and percentage of patients they see who have T2D in a typical week. All measures assessing primary variables (described below) were presented in a counterbalanced order to control for potential confounds created by order or sequence effects.

Attitudes toward patients with obesity. Participants completed the Attitudes about Treating Patients with Obesity Scale (ATPOS) [30,31], a 22-item measure that assesses healthcare provider attitudes about treating patients with obesity (e.g., "*I dislike treating with patients with obesity*," and "*I feel confident that I can provide quality care to patients with obesity*"). Participants provided their level of agreement to each statement on a 5-point scale, ranging from 1 = strongly disagree to 5 = strongly agree. An average score was calculated using the full 22-item scale ( $\alpha = 0.94$ ). Average scores were also calculated for three out of four subscales identified in previous research [32]: 1) dislike caring for patients with obesity (10 items; ( $\alpha = 0.93$ ); 2) lack of empathy (5 items;  $\alpha = 0.71$ ); and 3) perceived negative norms regarding patients with obesity (3 items;  $\alpha = 0.84$ ). The fourth subscale, preparedness to treat obesity, was excluded from analyses due to a low internal consistency ( $\alpha = 0.35$ ).

Mirroring the question format of the ATPOS, participants were asked an additional five questions to assess their perceptions of the extent to which patients with obesity are compliant with treatment recommendations, motivated to improve their diet, successful in making behavior changes, able to maintain weight loss, and how much they enjoy counseling these patients. This subscale of items was labeled as "perceptions of patient compliance". Items were rated on a 5-point scale (1 = not at all, 3 = somewhat, 5 = very much) and a mean score was calculated ( $\alpha = 0.75$ ).

Attitudes toward patients with type 2 diabetes. To assess provider attitudes about patients with T2D, participants were provided with a modified version of the Attitudes about Treating Patients with Obesity Scale (described above), in which each item was revised to refer to patients with T2D instead of patients with obesity. This scale is referred to as the Attitudes about Treating Patients with Diabetes Scale (ATPDS). All other content of the original items was retained, and participants provided their level of agreement to each statement on a 5-point scale, ranging from 1 = strongly disagree to 5 = strongly agree. An average score was calculated using the full 22-item scale ( $\alpha = 0.93$ ). Mean scores were also calculated for the three subscales described above: 1) dislike caring for patients with T2D (10 items; ( $\alpha = 0.92$ ); 2) lack of empathy (5 items;  $\alpha = 0.73$ ); and 3) perceived negative norms regarding patients with T2D (3 items;  $\alpha = 0.83$ ). The fourth subscale, preparedness to treat T2D, was excluded from analyses due to low internal consistency ( $\alpha =$ 0.31).

Participants were also asked the same additional five questions to assess their perceptions of treatment compliance among patients with T2D instead of obesity. Items were rated on a 5-point scale (1 = not at all, 3 = somewhat, 5 = very much) and an average score was calculated ( $\alpha = 0.71$ ).

Perceived controllability and blame of people with obesity and type 2

*diabetes.* Participants' beliefs regarding attributions of personal responsibility and blame of people with obesity were assessed using three questions previously tested [33] for assessing perceived blame of persons with stigmatized conditions, originally adapted from other scales [34,35]. Specifically, participants were asked to what extent they believe 1) obesity is controllable (1 = not at all under personal control to 5 = completely under personal control), 2) obesity is a person's fault (1 = no, not at all to 5 = yes, completely), and 3) an individual is personally responsible for having obesity (1 = not at all responsible to 5 = completely responsible). An average score was calculated ( $\alpha = 0.66$ ). To assess perceived controllability and blame for people with T2D, participants responded to modified versions of these three questions which referred to T2D instead of obesity, with all other item content remaining identical. An average score was calculated ( $\alpha = 0.62$ ).

Willpower subscale of the AFA Questionnaire. Participants completed the 3-item Willpower Subscale of the Anti-Fat Attitudes (AFA) scale [36], which assesses the extent that people believe obesity is attributed to lack of personal willpower. Items are rated on a 10-point Likert scale (0 = very strongly disagree, 9 = very strongly agree), with higher scores indicating stronger attributions that people with obesity lack willpower. An average score was obtained for this subscale ( $\alpha = 0.70$ ). To assess attributions of willpower among people with T2D, these three questions were modified to refer to people with T2D instead of focusing on body weight, with all other item content identical. ( $\alpha = 0.68$ ).

#### 2.3. Statistical analysis

Means, standard deviations, and frequencies were calculated for participant demographic characteristics, training background, and all measures of bias. Item-level and subscale-level differences between endorsement of weight stigma and T2D stigma were compared using paired samples t-tests. Next, the overall frequency of biased attitudes was examined by calculating the percentage of agreement across items of the bias scales. Lastly, relationships between measures of bias and participant characteristics were examined using correlations. Specifically, the relationships between endorsement of biased attitudes and age, body mass index (BMI), percent of patients with diabetes, number of patients with T2D, and years in practice were examined.

#### 3. Results

#### 3.1. Sample characteristics

In total, 379 participants completed the consent form and agreed to participate. Fifty-eight participants were excluded because they were not physicians, 32 were excluded because they did not treat diabetes, and 23 were screened out because they did not specialize in internal medicine or endocrinology. Thirteen participants were lost to attrition before they completed the screening questionnaire. Of the 253 eligible responses, an additional 48 were excluded based on improbable responses on demographic characteristics (e.g., age < 26).

The final sample included 205 physicians. Table 1 presents a summary of the sample characteristics. In total, 72% (n = 148) were men, 79% (n = 162) were White, and the average age was 40.33 (SD = 7.57). The mean BMI was 22.72 (SD = 3.91). Participants described their training background as MD (56%), Resident (27%), DO (15%), and Fellow (2%). Most specialized in internal medicine (68%) and 32% specialized in endocrinology. Almost half (48%) reported 5–10 years in their profession, followed by 10–15 years (30%), 15 + years (11%), and 1–5 years (10%). Working in an inpatient setting was most common (43%), followed by both inpatient and outpatient settings (37%) and outpatient only (20%). Most commonly, participants reported that 30–39% of their patients had T2D. On average, participants reported seeing 24 patients (SD = 19.87) with T2D per week.

#### Table 1

Sample Characteristics (N = 205).

Gender   57   27.8     Male   148   72.2     Male   148   72.2     Other   0   0.0     Race/Ethnicity   148   72.2     White, non-Hispanic, non-Latino   162   79.0     Black or African American   17   8.3     American Indian or Alaska Native   1   0.5     Asian or Pacific Islander   15   7.3     Mexican-American Latino or Hispanic   9   4.4     Other   1   0.5     Training Background   115   56.1     MD   115   56.1     DO   30   14.6     Resident   55   26.8     Fellow   55   26.8     Fellow   5   2.4     Specially Area   11   5.4     Internal Medicine   140   68.3     Endocrinology   65   31.7     Percentage of their patients that have T2D   20   9.8     6.0-79 %   61   29.8     80-100 %   35   17.1     Years in Pra			n		%
Female     57     27.8       Male     148     72.2       Other     0     0.0       Race/Ethnicity      0     0.0       White, non-Hispanic, non-Latino     162     79.0       Black or African American     17     8.3       American Indian or Alaska Native     1     0.5       Asian or Pacific Islander     15     7.3       Mexican-American Latino or Hispanic     9     4.4       Other     1     0.5       Training Background     115     56.1       DO     30     14.6       Resident     55     26.8       Fellow     5     24.4       Specialty Area     140     68.3       Endocrinology     65     31.7       Percentage of their patients that have T2D     11     5.4       O-19 %     11     5.4       20-39 %     60     29.2       40-59 %     61     29.8       80-100 %     35     17.1       Years in Practice     20.2 <td>Gender</td> <td></td> <td></td> <td></td> <td></td>	Gender				
Male14872.2Other00.0Race/Ethnicity0White, non-Hispanic, non-Latino16279.0Black or African American178.3American Indian or Alaska Native10.5Asian or Pacific Islander178.3Mexican-American Latino or Hispanic94.4Other94.4Other94.4Other94.4Other11556.1DO3014.6Resident5526.8Fellow52.4Specialty Area1154.Internal Medicine14068.3Endocrinology6531.7Percentage of their patients that have T2D029.240-59 %6029.240-59 %6129.880-100 %3517.1Years in Practice11.298.310-15 years2098.55-10 years209.85-10 years209.85-10 years2311.2Work setting1120.0More than 15 years2311.2Work setting4420.0Both Inpatient and Outpatient7536.6MSDMinMaxAge40.337.5726BMI22.723.911638.16Number of weekly patients with T2D23.5619.871	Female		57		27.8
Other     0     0.0       Race/Ethnicity     -     -       White, non-Hispanic, non-Latino     162     79.0       Black or African American     17     8.3       American Indian or Alaska Native     1     0.5       Asian or Pacific Islander     15     7.3       Mexican-American Latino or Hispanic     9     4.4       Other     1     0.5       Training Background     -     15     56.1       DO     30     14.6     14.6       Resident     55     26.8     24       Specialty Area     -     11     54.6       Internal Medicine     140     68.3     31.7       Percentage of their patients that have T2D     -     29.2     40.59 %       61     29.8     31.7     29.2     40.59 %       62     38.6     60.79 %     61     29.8       80-100 %     35     17.1     24.8     31.1       Years in Practice     20     9.8     5.10     29.8     30.2	Male		148		72.2
Race/Ethnicity   162   79.0     Black or African American   17   8.3     American Indian or Alaska Native   1   0.5     Asian or Pacific Islander   15   7.3     Mexican-American Latino or Hispanic   9   4.4     Other   1   0.5     Training Background   115   56.1     DO   30   14.6     Resident   55   2.6     Fellow   5   2.4     Specialty Area   110   68.3     Endocrinology   65   31.7     Percentage of their patients that have T2D   0   9.2     0-19 %   11   5.4     20-39 %   60   29.2     40-59 %   38   18.6     60-79 %   61   29.8     80-100 %   35   17.1     Years in Practice   11   5.4     1-5 years   20   9.8     5-10 years   99   48.3     10-15 years   62   30.2     More than 15 years   22   30.2     More than	Other		0		0.0
White, non-Hispanic, non-Latino16279.0Black or African American178.3American Indian or Alaska Native10.5Asian or Pacific Islander157.3Mexican-American Latino or Hispanic94.4Other10.5Training Background11556.1DO3014.6Resident5526.8Fellow5526.8Fellow5526.8Specialty Area1154.4Internal Medicine14068.3Endocrinology6531.7Percentage of their patients that have T2D115.420–39 %6029.240–59 %6129.880–100 %3517.1Years in Practice209.85–10 years209.85–10 years2331.2More than 15 years2331.2Work setting4120.0Both Inpatient and Outpatient7536.6Marit Mark Setting7536.6Mark Setting41.320.0Both Inpatient and Outpatient7536.6Mumber of weekly patients with T2D23.5619.87Number of weekly patients with T2D23.5619.87Age40.337.5726SMI22.723.911638.16Number of weekly patients with T2D23.5619.87100	Race/Ethnicity				
Black or African American178.3American Indian or Alaska Native10.5Asian or Pacific Islander157.3Mexican-American Latino or Hispanic94.4Other10.5Training Background11556.1DO3014.6Resident5526.8Fellow5526.8Fellow5526.8Specialty Area1154Internal Medicine14068.3Endocrinology6531.7Percentage of their patients that have T2D115.420-39 %6029.240-59 %6129.880-100 %3517.1Years in Practice209.85-10 years209.85-10 years2311.2More than 15 years2312.2Work setting4120.0Both Inpatient7536.6Mare than 15 years7536.6More than 15 years23.9116Age40.337.5726BMI22.723.9116Number of weekly patients with T2D23.5619.87Number of weekly patients with T2D23.5619.87Numb	White, non-Hispanic, non-Latino		162		79.0
American Indian or Alaska Native10.5Asian or Pacific Islander157.3Mexican-American Latino or Hispanic94.4Other94.4Other94.4Other94.4Other110.5Training Background11556.1DO3014.6Resident5526.8Fellow552.4Specialty Area14068.3Endocrinology6531.7Percentage of their patients that have T2D115.420–39 %6029.240–59 %6129.880–100 %3517.1Years in Practice115.41-5 years209.85–10 years6230.2More than 15 years2311.2More than 15 years6230.2More than 15 years6342.9Outpatient7536.6More than 15 years6320.0Both Inpatient and Outpatient7536.6Mare Age40.337.5726BMI22.723.911638.16Number of weekly patients with T2D23.5619.871	Black or African American		17		8.3
Asian or Pacific Islander   15   7.3     Mexican-American Latino or Hispanic   9   4.4     Other   9   4.4     Other   1   0.5     Training Background   115   56.1     DO   30   14.6     Resident   55   26.8     Fellow   5   2.4     Specialty Area   140   68.3     Endocrinology   65   31.7     Percentage of their patients that have T2D   11   5.4     0-19 %   111   5.4     20-39 %   60   29.2     40-59 %   38   18.6     60-79 %   38   18.6     60-79 %   31   29.8     80-100 %   33   17.1     Years in Practice   11   29.8     1-5 years   20   9.8     5-10 years   20   9.8     5-10 years   22   30.2     More than 15 years   23   11.2     Work setting   1   20.0     Hospital or Inpatient   88	American Indian or Alaska Native		1		0.5
Mexican-American Latino or Hispanic     9     4.4       Other     1     0.5       Training Background     115     56.1       MD     115     56.1       DO     30     14.6       Resident     55     26.8       Fellow     5     2.4       Specialty Area     140     68.3       Endocrinology     60     29.2       Adocrinology     60     29.2       40–19 %     11     5.4       20–39 %     60     29.2       40–59 %     38     18.6       60–79 %     61     29.8       80–100 %     29.2     34.5       99     48.3     10.1       17     74     29.8       5–10 years     20     9.8       5–10 years     21     30.2       More than 15 years     62     30.2       More than 15 years     62     30.2       More than 15 years     75     36.6       Outpatient     88     42.9 <td>Asian or Pacific Islander</td> <td></td> <td>15</td> <td></td> <td>7.3</td>	Asian or Pacific Islander		15		7.3
Other 1 0.5   Training Background 115 56.1   MD 130 14.6   Resident 55 2.4   Specialty Area 5 2.4   Specialty Area 140 68.3   Endocrinology 65 31.7   Percentage of their patients that have T2D 11 5.4   O-19 % 11 5.4   20-39 % 60 29.2   40-59 % 38 18.6   60-79 % 61 29.8   80-100 % 35 17.1   Years in Practice 11 29.8   1-5 years 20 9.8   5-10 years 62 30.2   More than 15 years 63 1   Outpatient 75 36.6   Doutpatient and Outpatient <td< td=""><td>Mexican-American Latino or Hispanic</td><td></td><td>9</td><td></td><td>4.4</td></td<>	Mexican-American Latino or Hispanic		9		4.4
Training Background   115   56.1     DO   30   14.6     DO   30   14.6     Resident   55   26.8     Fellow   5   2.4     Specialty Area   140   68.3     Endocrinology   65   31.7     Percentage of their patients that have T2D   11   5.4     20-39 %   60   29.2     40-59 %   38   18.6     60-79 %   61   29.8     80-100 %   35   17.1     Years in Practice   17.1   19.8     1-5 years   20   9.8     5-10 years   20.2   30.2     More than 15 years   20.2   30.2     More setting   11.2   20.2     Work setting   12.2   30.2     Hospital or Inpatient   88   42.9     Outpatient and Outpatient   75   36.6     Both Inpatient and Outpatient   75   36.6     Mare   SD   Min   Max     Age   40.33   7.57   26   72 <	Other		1		0.5
MD   115   56.1     DO   30   14.6     Resident   55   26.8     Fellow   55   2.4     Specialty Area   140   68.3     Endocrinology   65   31.7     Percentage of their patients that have T2D   11   5.4     0–19 %   11   5.4     20–39 %   60   29.2     40–59 %   61   29.2     60–79 %   61   29.8     80–100 %   35   17.1     Years in Practice   20   9.8     5–10 years   23   11.2     Work setting   11.2   30.2     Hospital or Inpatient   88   42.9     Outpatient   75   36.6     Both Inpatient and Outpatient   75   36.6     BMI   SD   Min   Max <	Training Background				
DO   30   14.6     Resident   55   26.8     Fellow   55   2.4     Specialty Area   140   68.3     Endocrinology   65   31.7     Percentage of their patients that have T2D   65   31.7     Percentage of their patients that have T2D   60   29.2     40–59 %   60   29.2     40–59 %   61   29.8     80–100 %   35   17.1     Years in Practice   36   9.8     5–10 years   20   9.8     5–10 years   22   30.2     More than 15 years   23   11.2     Work setting   11.2   20.9     More than 15 years   23   12.2     More than 15 years   88   42.9     Outpatient   75   36.6     Both Inpatient and Outpatient   75   36.6     Mare   22.72   3.91   16   38.16     Number of weekly patients with T2D   23.56   19.87   1   100	MD		115		56.1
Resident     55     26.8       Fellow     5     2.4       Specialty Area     140     68.3       Internal Medicine     140     68.3       Endocrinology     65     31.7       Percentage of their patients that have T2D     11     5.4       20–39 %     60     29.2       40–59 %     61     29.8       60–79 %     61     29.8       80–100 %     35     17.1       Years in Practice     17.1     17.1       Years in Practice     20     9.8       5–10 years     20     9.8       5–10 years     62     30.2       More than 15 years     62     30.2       More than 15 years     62     30.2       More setting     11.2     20.0     36.5       Outpatient     58     42.9     0.0       Outpatient and Outpatient     75     36.6       Mare Mare Mare Mare Mare Mare Mare Mare	DO		30		14.6
Fellow   5   2.4     Specialty Area   140   68.3     Internal Medicine   140   68.3     Endocrinology   60   29.2     0-19 %   11   5.4     20-39 %   60   29.2     40-59 %   38   18.6     60-79 %   61   29.8     80-100 %   38   18.6     60-79 %   61   29.8     80-100 %   20.2   9.8     5-10 pears   20   9.8     5-10 years   40.3   3.0     10-15 years   88   42.9     Outpatient   75   36.6     90 utpatient and Outpatient   75   36.6     91 matient and Outpatient   75   36.6     92.72 </td <td>Resident</td> <td></td> <td>55</td> <td></td> <td>26.8</td>	Resident		55		26.8
Specialty Area   140   68.3     Internal Medicine   140   68.3     Endocrinology   65   31.7     Percentage of their patients that have T2D   11   5.4     20–39 %   60   29.2     40–59 %   38   18.6     60-79 %   61   29.8     80–100 %   35   17.1     Years in Practice   20   9.8     5–10 years   20   9.8     5–10 years   62   30.2     More than 15 years   63   42.9     Outpatient   75   36.6     Doutpatient and Outpatient   75   36.6 <td>Fellow</td> <td></td> <td>5</td> <td></td> <td>2.4</td>	Fellow		5		2.4
Internal Medicine     140     68.3       Endocrinology     65     31.7       Percentage of their patients that have T2D     65     31.7       0–19 %     11     5.4       20–39 %     60     29.2       40–59 %     38     18.6       60–79 %     61     29.8       80–100 %     35     17.1       Years in Practice     1     20       1–5 years     20     9.8       5–10 years     99     48.3       10–15 years     62     30.2       More than 15 years     23     11.2       Work setting     11.2     20.0       Both Inpatient     88     42.9       Outpatient     75     36.6       SD     Min     Max       Age     40.33     7.57     26     72       BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     1	Specialty Area				
Endocrinology 65 31.7   Percentage of their patients that have T2D 11 5.4   0-19 % 11 5.4   20-39 % 60 29.2   40-59 % 38 18.6   60-79 % 61 29.8   80-100 % 35 17.1   Years in Practice 7 7   1-5 years 20 9.8   5-10 years 99 48.3   10-15 years 62 30.2   More than 15 years 23 11.2   Work setting 11 20.0   Both Inpatient 88 42.9   Outpatient 75 36.6   Both Inpatient and Outpatient 75 36.6   Mare Age 40.33 7.57 26 72   BMI 22.72 3.91 16 38.16   Number of weekly patients with T2D 23.56 19.87 1	Internal Medicine		140		68.3
Percentage of their patients that have T2D   11   5.4     0-19 %   11   5.4     20-39 %   60   29.2     40-59 %   61   29.8     60-79 %   61   29.8     80-100 %   35   17.1     Years in Practice   7   99     1-5 years   20   9.8     5-10 years   99   48.3     10-15 years   23   11.2     More than 15 years   23   30.2     More than 15 years   23   11.2     Work setting   1   20.0     Both Inpatient And Outpatient   75   36.6     Mathematic Modupatient   75   36.6     Mathematic Modupatient   75   36.6     Mathematic Modupatient   75   36.6     Multipatient and Outpatient   75   36.6     Multipatient and Outpatient   22.72   3.91   16   38.16     Number of weekly patients with T2D   23.56   19.87   1   100	Endocrinology		65		31.7
0-19 % 11 5.4   20-39 % 60 29.2   40-59 % 38 18.6   60-79 % 61 29.8   80-100 % 35 17.1   Years in Practice 20 9.8   5-10 years 20 9.8   5-10 years 62 30.2   More than 15 years 62 30.2   More than 15 years 62 30.2   More than 15 years 23 11.2   Work setting 41 20.0   Both Inpatient and Outpatient 75 36.6   M SD Min Max   Age 40.33 7.57 26 72   BMI 22.72 3.91 16 38.16   Number of weekly patients with T2D 23.56 19.87 1	Percentage of their patients that have T2D				
20-39 % 60 29.2   40-59 % 38 18.6   60-79 % 61 29.8   80-100 % 35 17.1   Years in Practice 9 48.3   1-5 years 20 9.8   5-10 years 62 30.2   More than 15 years 20 1.2   Work setting 41 20.0   Both Inpatient and Outpatient 75 36.6   M SD Min Max   Age 40.33 7.57 26 72   BMI 22.72 3.91 16 38.16   Number of weekly patients with T2D 23.56 19.87 1	0–19 %		11		5.4
40-59 % 38 18.6   60-79 % 61 29.8   80-100 % 35 17.1   Years in Practice 99 48.3   10-15 years 99 48.3   10-15 years 62 30.2   More than 15 years 62 30.2   Work setting 11.2   Hospital or Inpatient 88 42.9   Outpatient 41 20.0   Both Inpatient and Outpatient 75 36.6   M SD Min Max   Age 40.33 7.57 26 72   BMI 22.72 3.91 16 38.16   Number of weekly patients with T2D 23.56 19.87 1	20–39 %		60		29.2
60-79 % 61 29.8   80-100 % 35 17.1   Years in Practice 20 9.8   1-5 years 20 9.8   5-10 years 99 48.3   10-15 years 62 30.2   More than 15 years 23 11.2   Work setting 11.2 20.0   Both Inpatient 88 42.9   Outpatient 75 36.6   M SD Min Max   Age 40.33 7.57 26 72   BMI 22.72 3.91 16 38.16   Number of weekly patients with T2D 23.56 19.87 1 100	40–59 %		38		18.6
80–100 % 35 17.1   Years in Practice 7   1–5 years 20 9.8   5–10 years 99 48.3   10–15 years 62 30.2   More than 15 years 23 11.2   Work setting 7 36.6   Hospital or Inpatient 41 20.0   Both Inpatient and Outpatient 75 36.6   M SD Min Max   Age 40.33 7.57 26 72   BMI 22.72 3.91 16 38.16   Number of weekly patients with T2D 23.56 19.87 1 100	60–79 %		61		29.8
Years in Practice   20   9.8     1-5 years   20   9.8     5-10 years   99   48.3     10-15 years   62   30.2     More than 15 years   23   11.2     Work setting   11.2   20.0     Both Inpatient   88   42.9     Outpatient   75   36.6     Mark   20.0   30.2     Both Inpatient and Outpatient   75   36.6     Mark   SD   Min   Mark     Age   40.33   7.57   26   72     BMI   22.72   3.91   16   38.16     Number of weekly patients with T2D   23.56   19.87   1   100	80–100 %		35		17.1
1-5 years 20 9.8   5-10 years 99 48.3   10-15 years 62 30.2   More than 15 years 23 11.2   Work setting 41 20.0   Both Inpatient 75 36.6   More than 10 upatient 75 36.6   Mark Min Mark   Age 40.33 7.57 26   BMI 22.72 3.91 16 38.16   Number of weekly patients with T2D 23.56 19.87 1	Years in Practice				
5-10 years     99     48.3       10-15 years     62     30.2       More than 15 years     23     11.2       Work setting     41     20.0       Both Inpatient and Outpatient     75     36.6       Mark     Main     Main       Age     40.33     7.57     26     72       BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     1     100	1–5 years		20		9.8
10–15 years 62 30,2   More than 15 years 23 11.2   Work setting 88 42,9   Hospital or Inpatient 41 20,0   Both Inpatient and Outpatient 75 36.6   M SD Min Max   Age 40.33 7.57 26 72   BMI 22.72 3.91 16 38.16   Number of weekly patients with T2D 23.56 19.87 1 100	5–10 years		99		48.3
More than 15 years     23     11.2       Work setting     11.2       Hospital or Inpatient     88     42.9       Outpatient     41     20.0       Both Inpatient and Outpatient     75     36.6       M     SD     Min     Max       Age     40.33     7.57     26     72       BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     1     100	10–15 years		62		30.2
Work setting     88     42.9       Hospital or Inpatient     88     42.9       Outpatient     41     20.0       Both Inpatient and Outpatient     75     36.6       M     SD     Min     Max       Age     40.33     7.57     26     72       BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     1     100	More than 15 years		23		11.2
Hospital or Inpatient     88     42.9       Outpatient     41     20.0       Both Inpatient and Outpatient     75     36.6       M     SD     Min     Max       Age     40.33     7.57     26     72       BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     1     100	Work setting				
Outpatient     41     20.0       Both Inpatient and Outpatient     75     36.6       M     SD     Min     Max       Age     40.33     7.57     26     72       BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     1     100	Hospital or Inpatient		88		42.9
Both Inpatient and Outpatient     75     36.6       M     SD     Min     Max       Age     40.33     7.57     26     72       BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     1     100	Outpatient		41		20.0
M     SD     Min     Max       Age     40.33     7.57     26     72       BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     100	Both Inpatient and Outpatient		75		36.6
Age     40.33     7.57     26     72       BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     1     100		Μ	SD	Min	Max
BMI     22.72     3.91     16     38.16       Number of weekly patients with T2D     23.56     19.87     1     100	Age	40.33	7.57	26	72
Number of weekly patients with T2D 23.56 19.87 1 100	BMI	22.72	3.91	16	38.16
	Number of weekly patients with T2D	23.56	19.87	1	100

#### 3.2. Hypothesis testing

Table 2 presents the descriptive findings of the primary measures of bias towards patients with obesity and patients with T2D. The mean score on the Attitudes about Treating Patients with Type 2 Diabetes Scale was 2.63 (SD = 0.79), which is significantly lower than the mean score of the Attitudes about Treating Patients with Obesity Scale (M =2.78, SD = 0.80), p < .001. This pattern was consistent across subscales; participants endorsed significantly greater biased attitudes towards patients with obesity than patients with T2D (Range p < .001 to p =.020; Table 2). The mean score on the Perceived Controllability and Blame of People with Type 2 Diabetes was 3.64 (SD = 0.76), which was significantly lower than the mean score on the Perceived Controllability and Blame of People with Obesity (M = 3.74, SD = 0.71), p = .029, with both being indicative of biased attitudes. The pattern was consistent on other scales assessing participant beliefs about patients' treatment compliance; participants believed that individuals with obesity were significantly less likely to be compliant with treatment recommendations than individuals with T2D, p = .006. Mean scores for the AFA-Willpower subscale were also indicative of biased attitudes for both patients with obesity and patients with T2D, with significantly greater bias towards patients with obesity, p < .001.

Table 3 summarizes participants' agreement with individual items of the Attitudes about Treating Patients with Type 2 Diabetes Scale. Overall, participants endorsed feeling professionally prepared (n = 177; 86%) and confident (n = 174; 85%) in their abilities to provide quality care to patients with T2D. Additionally, participants reported they feel that it is important to treat patients with T2D with compassion and

#### Table 2

Descriptive Statistics for Outcome Variables (N = 205).

	Obesity				Type 2 Diabetes				Differences
	Μ	SD	Min	Max	Μ	SD	Min	Max	
Attitudes about Treating Patients with Obesity/T2D Scale	2.78	0.80	1.00	4.18	2.63	0.79	1.05	4.14	t(203) = -5.60, p < .001
Lack of Empathy Subscale		0.84	1.00	4.40	2.68	0.90	1.00	4.40	t(204) = -3.53, p = .001
Dislike of Caring for Subscale		1.01	1.00	4.80	2.71	0.96	1.10	4.70	t(203) = -5.77, p < .001
Perceived Negative Norms Subscale	3.02	1.17	1.00	5.00	2.90	1.16	1.00	5.00	t(204) = -2.35, p = .020
Perceptions of Patient Compliance	3.81	0.64	1.40	5.00	3.88	0.61	1.80	5.00	t(200) = 2.78, p = .006
Perceived Controllability and Blame	3.74	0.71	1.67	5.00	3.64	0.76	1.00	5.00	t(202) = -2.20, p = .029
AFA-Willpower Subscale	6.24	1.72	0.67	9.00	5.94	1.80	0.33	9.00	t(204) = -3.75, p < .001

Note: Each scale and subscale score are the average of the relevant items.

respect (n = 159; 78%), enjoy counseling patients with T2D (n = 159; 78%), and find it professionally rewarding (n = 157; 77%). However, a considerable percentage of participants also reported that treating patients with T2D was more emotionally draining (n = 90; 44%), stressful (n = 78; 38%), and frustrating (n = 75; 37%) than treating a patient without diabetes. Further, approximately 1/3 of participants reported it is difficult to feel empathy for patients with T2D (n = 65; 32%) and being repulsed by treating patients with T2D (n = 68; 33%). A substantial percentage of participants also endorsed negative stereotypes about patients with T2D including views that they lack motivation to make lifestyle changes (90; 44%), tend to be lazy (n = 79; 39%), and are often non-compliant with treatment recommendations (n = 90; 44%). Many also reported that they have heard or witnessed other professionals in their field make negative comments about patients with T2D (n = 90; 44%).

Similar patterns emerged across items assessing attitudes towards treating patients with obesity; participants felt prepared (n = 175; 85%) and confident (n = 180; 88%) in their abilities to provide care but endorsed negative stereotypes about patients with obesity. Over half of physicians viewed patients with obesity as lazy (n = 116; 57%), lacking motivation to make lifestyle changes (n = 112; 55%), and often non-compliant with treatment recommendations (n = 108; 53%). Almost half reported that they have heard or witnessed other professionals in their field make negative comments about patients with obesity (n = 93; 45%).

Overall, participants tended to endorse higher bias towards patients with obesity than towards patients with T2D. Specifically, on approximately half of the items on the attitude measures, physicians endorsed significantly greater weight-related bias than T2D-related bias (Table 3). This included higher endorsement of negative stereotypes about patients with obesity, greater skepticism that patients with obesity would be compliant with treatment recommendations, and greater endorsement of negative personal feelings about treating these patients (i.e., feeling disgust, frustration, etc.) compared to patients with T2D. Notably, there were no items on these measures in which physicians endorsed significantly greater bias towards individuals with T2D than individuals with obesity.

Table 4 summarizes participants beliefs about the controllability of T2D and obesity. Most participants endorsed beliefs that individuals with T2D could lose at least some part of their weight through a little exercise (n = 187; 91%), are personally responsible for developing T2D (n = 144; 70%), and that some people have T2D because they have no willpower (n = 144; 70%). Participants responded in a similar pattern to individuals with obesity; high percentages of participants endorsed beliefs that individuals with obesity could lose at least come part of their weight through a little exercise (n = 181; 88%), are personally responsible for 'becoming obese' (n = 146; 71%), and that some people have obesity because they lack willpower (n = 155; 76%).

Finally, Table 5 summarizes associations between participant characteristics and their endorsement of bias towards individuals with T2D and individuals with obesity. Age was significantly negatively correlated with several bias-related outcomes such that younger physicians endorsed worse overall attitudes towards patients with T2D (p = .007), greater lack of empathy (p = .020), more dislike of caring for patients with T2D (p = .003), and poorer attitudes from people in their field (p = .010). These patterns were the same for obesity; younger age was associated with worse overall attitudes towards patients with obesity (p = .016), greater lack of empathy (p = .025), more dislike of caring for patients with obesity (p = .017), and poorer attitudes from people in their field (p = .004). Younger age was also significantly associated with greater belief that T2D is controllable (p = .040).

There were also several significant relationships related to participant level of experience in the field. Fewer years in practice was significantly associated with worse overall attitudes towards patients with T2D (p < .001), greater lack of empathy (p = .001), more dislike of caring for patients with T2D (p < .001), and poorer attitudes from people in their field (p = .006). Similarly, years in practice was significantly negatively associated with attitudes towards patients with obesity (p = .007), lack of empathy (p = .012), dislike of caring for patients with obesity (p = .006), belief that individuals with obesity lack willpower (p = .030), and witnessing negative attitudes from people in their field (p = .008).

There were several significant positive correlations between the percentage of patients (but not number of patients) with T2D and bias. Treating a greater percentage of patients with T2D was significantly associated with worse overall attitudes towards patients with T2D (p =.034), greater lack of empathy for both patients with T2D (p = .001) and patients with obesity (p = .010), and more dislike of caring for patients with T2D (p = .034). Additionally, treating a higher percentage of patients with T2D was significantly associated with higher endorsement of the personal controllability of both T2D (p < .001) and obesity (p <.001), as well as greater belief that patients with T2D lack willpower (p = .020). In contrast, treating a higher percentage of patients with T2D was significantly associated with greater belief that both patients with T2D (p < .001) and patients with obesity (p < .001) will be compliant with treatment recommendations. Finally, lower BMI among physicians was associated with greater belief that T2D is controllable (p = .023), obesity is controllable (p = .014) and that individuals with obesity lack willpower (p = .027).

#### 4. Discussion

To our knowledge, this is the first study to systematically assess diabetes stigma among physicians treating patients with T2D. Overall, physicians endorsed feeling confident and prepared to treat patients with T2D, but consistently endorsed biased attitudes towards and negative stereotypes about these patients. At least 1/3 (39%-44%) of physicians viewed patients with T2D as lazy, non-compliant with treatment, and lacking motivation for making lifestyle changes. Additionally, more than 2/3 of physicians believed that patients have at least partial control over, or responsibility for, their development of T2D. Collectively, responses across measures indicate a moderate level of stigma towards individuals with T2D. These findings are consistent with prior evidence documenting that 40–60% of patients with T2D report

#### Table 3

Physician Attitudes about Treating Patients with Type 2 Diabetes and Patients with Obesity.

Scale Items Assessing Attitudes toward	Physician	Agreement	Item level		
Patients with 12D and Obesity	(%) Obesity	Type 2 Diabetes	differences		
Lack of Empathy Subscale <sup>b</sup>					
I feel that it is important to treat patients with obesity/type 2 diabetes with compassion and respect	79.5	77.5	t(204) = 0.62, p = .267		
Patients with obesity/type 2 diabetes lack motivation to make lifestyle	54.6	43.9	t(204) = -3.23, p < 0.01		
changes. Patients with obesity/type 2 diabetes tend to be lazy.	56.6	38.6	t(204) = -5.67, p < 001		
It is difficult to feel empathy for a patient with obesity/type 2 diabetes.	31.7	31.7	t(204) = -0.62, p = .269		
Treating a patient with obesity/type 2 diabetes repulses me Dislike Caring for Subscale <sup>b</sup>	32.2	33.2	t(204) = 0.00, p = .500		
Patients with obesity/type 2 diabetes are often non-compliant with treatment recommendations.	52.7	43.9	t(204) = -2.60, p = .005		
Treating a patient with obesity/type 2 diabetes is more emotionally draining than treating a non-obese/ non-diabetic patient	50.2	43.9	t(204) = -3.75, <i>p</i> < .001		
Treating a patient with obesity/type 2 diabetes is more stressful than treating a non-obese/non-diabetic patient	44.9	38.0	t(204) = -1.16, p = .124		
Treating a patient with obesity/type 2 diabetes is more frustrating that treating a patient without this disease.	41.0	36.5	t(204) = -2.20, p = .015		
Patients with obesity/type 2 diabetes can be difficult to deal with.	40.0	35.1	t(203) = -1.35, p = .089		
I would rather treat a non-obese/non- diabetic patient than a patient with obseity/type 2 diabetes	36.6	33.7	t(204) = -2.73, p = 003		
I often feel frustrated with patients who have obesity/type 2 diabetes	38.6	32.2	t(204) = -3.19, p < 001		
I dislike treating patients with obesity/ type 2 diabetes.	28.8	23.4	t(204) = -4.39, p < 001		
I feel disgust when treating a patient with obesity/type 2 diabetes.	27.8	23.4	t(204) = -3.31, p < 001		
I feel more irritated when I am treating a patient with obesity/type 2 diabetes than a non-obese/non-	32.2	20.0	t(204) = -4.20, p < .001		
diabetic patient.					
I have heard/witnessed other	45.4	43.9	t(204) =		
professionals in my field make negative comments about patients with obesity/type 2 diabetes			-0.23, p =.410		
Health care providers feel uncomfortable when caring for patients with obesity/type 2 diabetes.	38.1	35.1	t(204) = -2.14, p = .017		
My colleagues tend to have negative attitudes toward patients with obesity/type 2 diabetes	37.1	34.6	t(204) = -2.63, p = 005		
Profession-Related Attitudes about Obesity/	Type 2 Diab	etes Questions <sup>b</sup>			
I feel professionally prepared to effectively treat patients with obesity/type 2 diabetes	85.4	86.3	t(204) = -0.86, p = .196		
I feel confident that I provide quality care to patients with obesity/type 2 diabetes	87.8	84.9	t(204) = 1.54, p = .062		
Treating patients with obesity/type 2 diabetes is professionally rewarding.	74.1	76.6	t(204) = 0.20, p = .422		

#### Table 3 (continued)

Scale Items Assessing Attitudes toward Patients with T2D and Obesity	Physician (%)	Agreement	Item level differences <sup>a</sup>		
	Obesity	Type 2 Diabetes			
Other health providers in my field often have negative stereotypes toward patients with obesity/type 2 diabetes. <i>Percentions of Patient Compliance</i> <sup>6</sup>	43.9	42.9	t(204) = -1.35, $p =$ .089		
How much do you enjoy/do you enjoy counseling and working with patients with obesity/type 2 diabetes?	73.2	77.5	t(203) = 1.54, p = .062		
In general, how successful do you think patients with obesity/type 2 diabetes can be in making behavior changes?	68.8	70.7	t(203) = 0.45, p = .325		
How much confidence do you have that patients with obesity/type 2 diabetes can maintain weight loss, once it is achieved?	59.5	66.8	t(203) = 2.79, p = .003		
In general, how motivated do you think patients with obesity/type 2 diabetes are to change their diet?	59.0	63.9	t(203) = 0.38, p = .352		
In general, how compliant do you think patients with obesity/type 2 diabetes are with treatment recommendations?	59.0	61.1	t(204) = 1.33, p = .093		

<sup>a</sup> Paired sample t-tests were conducted using the full 1–5 Likert scale for each item.

<sup>b</sup> Agreement = Responses of "Agree" or "Strongly Agree"; <sup>c</sup> Agreement = Responses of "4" or "Very Much".

#### Table 4

Physicians' Attributions of Controllability and Blame of Patients with Type 2 Diabetes and Obesity.

Scale items	Percentage of Physicians (%)								
	Obesity	Type 2 Diabetes							
Perceived Controllability and Blame of People with Obesity and Type 2 Diabetes									
In your opinion, how controllable is the cause of obesity/ type 2 diabetes?	71.3	70.2							
In your opinion, is an individual personally responsible for becoming obese/developing type 2 diabetes?	63.9	72.2							
In your opinion, do you think it is a person's own fault that he/she is obese/has type 2 diabetes?	57.1	47.3							
People who weigh too much/with type 2 diabetes could lose at least some part of their weight through a little exercise.	88.4	91.1							
Some people are obese/have type 2 diabetes because they have no willpower.	75.6	70.3							
Obese people/People with type 2 diabetes tend to be obese/diabetic pretty much through their own fault.	76.1	68.8							

Note: Percentage of Physicians = Responses of 4 or 5 (Completely) for the Perceived Controllability and Blame of People with Obesity and Type 2 Diabetes and Responses of 5-9 (Strongly Agree) for the Willpower Subscale of the Anti-Fat Attitudes Scale.

being stigmatized in a healthcare setting [12] and 44% feel stigmatized about their weight by their physician [12].

Our study also provides the first comparison of weight stigma and diabetes stigma among physicians. Results showed that physicians have moderate levels of bias against both patients with T2D and patients with obesity. While their endorsement of weight bias was generally worse than their biased attitudes about patients with T2D, the differences between the mean scale scores on these attitude measures were small. These findings may be explained by the overlap in stereotypes and beliefs about personal responsibility and controllability associated with both body weight and T2D. For example, because obesity is often viewed as a causal risk factor of T2D, it is possible that the weight-based

#### Table 5

Associations between Participant Characteristics and Endorsement of Weight Stigma and Diabetes Stigma.

Scale	Obesity					Type 2 Diabetes				
	Age	BMI	% of patients with T2D	# of patients with T2D weekly	Yrs in Practice	Age	BMI	% of patients with T2D	# of patients with T2D weekly	Yrs in Practice
Attitudes towards patients with Obesity/T2D	-0.17**	0.05	0.11	-0.06	-0.19**	-0.19**	0.06	0.15*	-0.02	-0.25***
Lack of Empathy Subscale	-0.16**	-0.01	0.18**	-0.02	-0.18**	-0.16*	0.02	0.22**	0.06	-0.24**
Dislike of Caring for	-0.17**	0.08	0.12	-0.05	-0.19**	-0.21**	0.08	0.15*	-0.04	-0.27***
Perceived Negative Norms Subscale	-0.20**	0.03	0.05	-0.11	-0.19**	-0.18**	-0.01	0.05	-0.08	-0.19**
Perceptions of Patient Compliance	-0.01	-0.12	0.29***	0.05	0.02	-0.03	-0.08	0.26***	0.04	0.05
Perceived Controllability and Blame of People with Obesity/T2D	-0.11	-0.17*	0.27***	0.01	-0.12	-0.15*	-0.16*	0.28***	0.08	-0.11
AFA-Willpower Subscale	-0.07	-0.15*	0.09	0.06	-0.15*	-0.03	-0.10	0.16**	0.10	-0.10

stereotypes that physicians have about individuals with obesity extend to individuals with T2D. It may be difficult to separate these two types of bias as obesity and T2D frequently co-occur [16]. Given that both weight stigma and T2D stigma are associated with negative health outcomes [18,37], individuals with T2D may be at greater risk of being stigmatized by their healthcare provider for both their weight and diabetes, facing greater, and potentially multiplied, health risks.

Findings of our study identified several individual differences associated with endorsement of bias. First, biased attitudes towards individuals with T2D and obesity were worse among physicians who were younger with less experience. This finding is consistent with existing evidence of weight bias present among students in medical training [38] and highlights the need for early intervention among physicians, particularly in medical school and during residency. In addition to physician age and experience, the percentage of patients with T2D on a physician's caseload may be a relevant factor in endorsement of bias. Specifically, having a higher percentage of patients with T2D was associated with greater lack of empathy towards patients with T2D and obesity and greater belief that both obesity and T2D are controllable. These findings suggest that physician biases are not limited to those who inexperienced or new to treating diabetes. Other factors not examined in our survey, such as physician burnout with higher caseloads, warrant future exploration in the context of stigma toward patients with T2D.

There have been increasing calls for efforts to address weight stigma in the medical community at large [39–41]. Our study findings reiterate the importance of stigma reduction education and interventions for practicing medical providers. Further, they underscore the need for these interventions to target diabetes stigma in addition to weight stigma. Our findings highlight key steps for future research, while acknowledging several study limitations. First, while our sample of physicians reflects a random sub-sample of the ISA physician panel, it may not be representative of the panel or the broader population of U.S. physicians with these medical specialties. For example, the study participants were primarily White and male-identifying; this limits generalizability to the population of practicing primary care physicians in the U.S., which includes more women and greater racial and ethnic diversity [44,45]. Our sample composition thus precluded the ability to examine the impact of physician gender and race on endorsement of bias, and additional studies are needed to confirm the presence and prevalence of bias among larger and more diverse samples of physicians who treat T2D. Second, the present research was cross-sectional. More research is needed to study the impact of provider biases on patients with T2D. For example, it is important to understand how physician bias impacts the quality of care they provide for their patients with T2D and on other healthcare-related patient outcomes. For example, future research should consider whether physician bias is associated with greater healthcare avoidance among their patients with T2D. Patients with T2D already face a series of barriers to engaging in health-promoting behaviors including complicated medication regimes [42], lack of social support [43], and monetary expenses [43]. Therefore, it is crucial to better understand the role of stigma as an additional psychosocial barrier to diabetes care.

This study provides the first examination of provider biases towards patients with T2D and provides a direct comparison of these patterns to weight stigma. Our findings underscore the pervasive nature of weight stigma in healthcare settings and suggest that this stigma impacts individuals with T2D as well. These findings highlight the need for more research on diabetes stigma among physicians and how it affects patient health outcomes. More broadly, this study represents a clear rationale for addressing diabetes stigma by providing much-needed data on physician attitudes to inform stigma reduction efforts in healthcare.

#### Funding

This study was supported by an internal research grant from the Office for Vice President of Research at the University of Connecticut. The funding source had no role in the study design or preparation of this manuscript.

#### **Declaration of Competing Interest**

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rebecca Puhl reports a relationship with Eli Lilly and Company that includes: consulting or advisory and funding grants. Rebecca Puhl reports a relationship with WW International Inc that includes: funding grants.

#### Acknowledgements

The authors thank the participants in the ISA panel who provided information about their experiences treating type 2 diabetes, allowing this study to be carried out.

#### References

- Speight J, et al. Back to the future: 25 years of 'Guidelines for encouraging psychological well-being' among people affected by diabetes. Diabet Med 2020;37 (8):1225–9. https://doi.org/10.1111/dme.14165.
- [2] International Diabetes Federation. IDF strategic plan 2013–2015. Brussels: IDF; 2013.
- [3] American Diabetes Association. Health equity bill of rights. Available from: https://www.diabetes.org/sites/default/files/202008/Health%20Equity%20Bill\_2n d\_v2.pdf [cited 2023 February 15].
- [4] Holmes-Truscott E, et al. Diabetes stigma is associated with negative treatment appraisals among adults with insulin-treated Type 2 diabetes: results from the

second Diabetes MILES-Australia (MILES-2) survey. Diabet Med 2018;35(5): 658–62. https://doi.org/10.1111/dme.13598.

- [5] Browne JL, et al. 'I call it the blame and shame disease': a qualitative study about perceptions of social stigma surrounding type 2 diabetes. BMJ Open 2013;3(11): e003384. https://doi.org/10.1136/bmjopen-2013-003384.
- [6] Browne JL, et al. Measuring the stigma surrounding type 2 diabetes: development and validation of the type 2 diabetes stigma assessment scale (DSAS-2). Diabetes Care 2016;39(12):2141–8. https://doi.org/10.2337/dc16-0117.
- [7] Holmes-Truscott E, et al. Psychosocial moderators of the impact of diabetes stigma: results from the second diabetes MILES–Australia (MILES-2) study. Diabetes Care 2020;43(11):2651–9. https://doi.org/10.2337/dc19-2447.
- [8] Kato A, et al. Associations between diabetes duration and self-stigma development in Japanese people with type 2 diabetes: a secondary analysis of cross-sectional data. BMJ Open 2021;11(12):e055013. https://doi.org/10.1136/bmjopen-2021-055013.
- Kato A, Yamauchi T, Kadowaki T. A closer inspection of diabetes-related stigma: why more research is needed. Diabetology Int 2020;11:73–5. https://doi.org/ 10.1007/s13340-019-00421-w.
- [10] Kato A, et al. How self-stigma affects patient activation in persons with type 2 diabetes: a cross-sectional study. BMJ Open 2020;10(5):e034757.
- [11] Kato A, et al. Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study. BMJ Open 2017;7(3):e013425. https://doi.org/10.1136/bmjopen-2016-013425.
- [12] Himmelstein M, Puhl R. At multiple fronts: diabetes stigma and weight stigma in adults with type 2 diabetes. Diabet Med 2021;38(1):e14387. https://doi.org/ 10.1111/dme.14387.
- [13] Liu NF, et al. Stigma in people with type 1 or type 2 diabetes. Clin Diab 2017;35(1): 27–34. https://doi.org/10.2337/cd16-0020.
- [14] Puhl RM, et al. Weight stigma and diabetes stigma in US adults with type 2 diabetes: associations with diabetes self-care behaviors and perceptions of health care. Diabetes Res Clin Pract 2020;168:108387. https://doi.org/10.1016/j. diabres.2020.108387.
- [15] Puhl RM, Himmelstein MS, Speight J. Weight stigma and diabetes stigma: implications for weight-related health behaviors in adults with type 2 diabetes. Clin Diab 2022;40(1):51–61. https://doi.org/10.2337/cd20-0071.
- [16] Center for Disease Control and Prevention. National diabetes statistics report. In: Estimates of diabetes and its burden in the United States. Atlanta, GA: U.S. Department of Health and Human Services; 2020.
- [17] Spahlholz J, et al. Obesity and discrimination-a systematic review and metaanalysis of observational studies. Obes Revs 2016;17(1):43–55. https://doi.org/ 10.1111/obr.12343.
- [18] Potter L, et al. Attributing discrimination to weight: associations with well-being, self-care, and disease status in patients with type 2 diabetes mellitus. J Behav Med 2015;38:863–75. https://doi.org/10.1007/s10865-015-9655-0.
- [19] Teixeira ME, Budd GM. Obesity stigma: a newly recognized barrier to comprehensive and effective type 2 diabetes management. J Am Acad Nurse Pract 2010;22(10):527–33. https://doi.org/10.1111/j.1745-7599.2010.00551.x.
- [20] Puhl RM, et al. Overcoming weight bias in the management of patients with diabetes and obesity. Clin Diab 2016;34(1):44–50. https://doi.org/10.2337/ diaclin.34.1.44.
- [21] Phelan SM, et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes Revs 2015;16(4):319–26. https://doi.org/10.1111/ obr.12266.
- [22] Puhl RM, et al. The roles of experienced and internalized weight stigma in healthcare experiences: perspectives of adults engaged in weight management across six countries. PLoS ONE 2021;16(6):e0251566. https://doi.org/10.1371/ journal.pone.0251566.
- [23] Sabin JA, Marini M, Nosek BA. Implicit and explicit anti-fat bias among a large sample of medical doctors by BMI, race/ethnicity and gender. PLoS ONE 2012;7 (11):e48448. https://doi.org/10.1371/journal.pone.0048448.

- [24] Tomiyama AJ, et al. Associations of weight stigma with cortisol and oxidative stress independent of adiposity. Health Psychol 2014;33(8):862. https://doi.org/ 10.1037/hea0000107.
- [25] Sutin AR, et al. Perceived weight discrimination and C-reactive protein. Obesity 2014;22(9):1959–61. https://doi.org/10.1002/oby.20789.
- [26] Pearl RL, et al. Association between weight bias internalization and metabolic syndrome among treatment-seeking individuals with obesity. Obesity 2017;25(2): 317–22. https://doi.org/10.1002/oby.21716.
- [27] Sutin AR, Terracciano A. Perceived weight discrimination and obesity. PLoS ONE 2013;8(7):e70048. https://doi.org/10.1371/journal.pone.0070048.
- [28] Panza GA, et al. The effects of an acute weight stigma exposure on cardiovascular reactivity among women with obesity and hypertension: a randomized trial. J Psychosom Res 2023;165:111124. https://doi.org/10.1016/j. jpsychores.2022.111124.
- [29] Tsenkova VK, et al. Perceived weight discrimination amplifies the link between central adiposity and nondiabetic glycemic control (HbA1c). Ann Behav Med 2011; 41(2):243–51. https://doi.org/10.1007/s12160-010-9238-9.
- [30] Puhl RM, Luedicke J, Grilo CM. Obesity bias in training: attitudes, beliefs, and observations among advanced trainees in professional health disciplines. Obesity 2014;22(4):1008–15. https://doi.org/10.1002/oby.20637.
- [31] Puhl RM, et al. Weight bias among professionals treating eating disorders: attitudes about treatment and perceived patient outcomes. Int J Eat Disord 2014;47(1): 65–75. https://doi.org/10.1002/eat.22186.
- [32] Phelan SM, et al. The role of weight bias and role-modeling in medical students' patient-centered communication with higher weight standardized patients. Patient Educ Couns 2021;104(8):1962–9. https://doi.org/10.1016/j.pec.2021.01.003.
- [33] DePierre JA, Puhl RM, Luedicke J. A new stigmatized identity? Comparisons of a "food addict" label with other stigmatized health conditions. Basic Applied Soc Psychol 2013;35(1):10–21. https://doi.org/10.1080/01973533.2012.746148.
- [34] Corrigan P, et al. An attribution model of public discrimination towards persons with mental illness. J Health Soc Behav 2003:162–79. https://doi.org/10.2307/ 1519806.
- [35] Cunningham JA, Sobell LC, Chow VM. What's in a label? The effects of substance types and labels on treatment considerations and stigma. J Stud Alcohol 1993;54 (6):693–9. https://doi.org/10.15288/jsa.1993.54.693.
- [36] Crandall CS. Prejudice against fat people: ideology and self-interest. J Pers Soc Psychol 1994;66(5):882.
- [37] Pearl RL, Puhl RM. Weight bias internalization and health: a systematic review. Obes Revs 2018;19(8):1141–63. https://doi.org/10.1111/obr.12701.
- [38] Phelan SM, et al. Implicit and explicit weight bias in a national sample of 4,732 medical students: the medical student CHANGES study. Obesity 2014;22(4): 1201–8. https://doi.org/10.1002/oby.20687.
- [39] Alberga AS, et al. Weight bias: a call to action. J Eat Disord 2016;4(1):1–6. https:// doi.org/10.1186/s40337-016-0112-4.
- [40] Flint SW. Time to end weight stigma in healthcare. EClinicalMedicine 2021:34. https://doi.org/10.1016/j.eclinm.2021.100810.
- [41] Rubino F, et al. Joint international consensus statement for ending stigma of obesity. Nat Med 2020;26(4):485–97. https://doi.org/10.1038/s41591-020-0803x.
- [42] Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence 2016:1299–307. https://doi.org/10.2147/PPA.S106821.
- [43] Daly JM, et al. An assessment of attitudes, behaviors, and outcomes of patients with type 2 diabetes. J Am Board Fam Med 2009;22(3):280–90. https://doi.org/ 10.3122/jabfm.2009.03.080114.
- [44] Association of American Medical Colleges. What's your specialty: new data show the choices of America's doctors by gender, race, and age. Available from: https ://www.aamc.org/news/what-s-your-specialty-new-data-show-choices-america-sdoctors-gender-race-and-age.
- [45] Association of American Medical Colleges. Diversity in Medicine. Available from: https://www.aamc.org/data-reports/workforce/data/figure-18-percentage-all-acti ve-physicians-race/ethnicity-2018.